Gilteritinib vs Quizartinib
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Acute Myeloid Leukemia
Shared mechanism: FLT3 · full Acute Myeloid Leukemia pipeline
Gilteritinib
Marketed by Astellas Pharma
NCT02997202 · Phase 3 · completed
This was a randomized, quadruple-blind, placebo-controlled trial with 178 participants per group and a hard clinical primary endpoint of relapse-free survival. The primary endpoint was not statistically significant (hazard ratio 0.679; p=0.0518), so the results provide well-controlled but inconclusive evidence of benefit.
Next expected readout: December 2026 · NCT06001788 (registry estimate)
Reported efficacy
Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Overall Survival (OS) (From the date of randomization until the date of death from any cause ( maximum duration up to 79 months)): Randomized Cohort: Gilteritinib + AZA 9.82 months (95% CI 8.11 to 13.17) | Randomized Cohort: Gilteritinib 5.24 months (95% CI 2.46 to 15.18) vs Randomized Cohort: AZA 9.23 months (95% CI 4.34 to 12.55) (missed)
Result source: NCT02752035
Quizartinib
Marketed by Daiichi Sankyo and partners
NCT02668653 · Phase 3 · completed
The trial randomized 539 participants to quizartinib plus chemotherapy or placebo plus chemotherapy, with participants, investigators, and outcome assessors masked. Its hard primary endpoint, overall survival, was met in favor of quizartinib, with a statistically significant hazard ratio of 0.776 (p=0.0324).
Next expected readout: May 2027 · NCT03793478 (registry estimate)
Reported efficacy
Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Overall Survival in Participants With Newly Diagnosed FLT3-ITD (+) Acute Myeloid Leukemia (Date of randomization to the date of death due to any cause, up to approximately 3 years after enrollment): Quizartinib 31.9 months vs Placebo 15.1 months (95% CI 13.2 to 26.2) (met)
Result source: NCT02668653
Results for Acute Myeloid Leukemia
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | Gilteritinib | Quizartinib |
|---|---|---|
| OS, median | 9.8 vs 9.2vs AZANCT027520353 other results
| 31.9 vs 15.1+16.8 vs placeboNCT026686538 other results
|
| Complete remission | 21.1% vs 10.5%vs Salvage ChemotherapyNCT024219394 other results
| 2.6%bNCT015656681 other result
|
| Event-free survival, median | 0.0 vs 0.0vs AZANCT027520355 other results
| 0.0 vs 0.7−0.7 vs placeboNCT026686535 other results
|
| Duration of response, median | 14.8 vs 1.8vs Salvage ChemotherapyNCT02421939 | 3.6bNCT009892613 other results
|
OS, median
- Gilteritinib
- 9.8 vs 9.2vs AZANCT02752035
3 other results
- 9.3 vs 5.6 NCT02421939
- 5.2 vs 9.2 NCT02752035
- 5.8 NCT03730012
- Quizartinib
- 31.9 vs 15.1+16.8 vs placeboNCT02668653
8 other results
- 6.2 vs 4.7 NCT02039726
- 5.5 NCT00989261
- 6.3 NCT01565668
- 4.8 NCT01565668
- 5.9 NCT00989261
- 7.9 NCT02984995
- 4.4 NCT00989261
- 5.8 NCT00989261
Complete remission
- Gilteritinib
- 21.1% vs 10.5%vs Salvage ChemotherapyNCT02421939
4 other results
- 25.8% vs 17.5% NCT02752035
- 9.1% vs 17.5% NCT02752035
- 33.3% NCT03730012
- 0% NCT03730012
- Quizartinib
- 2.6%bNCT01565668
1 other result
- 5.3% NCT01565668
Event-free survival, median
- Gilteritinib
- 0.0 vs 0.0vs AZANCT02752035
5 other results
- 2.8 vs 0.7 NCT02421939
- 0.0 vs 0.0 NCT02752035
- 14.1 vs 6.7 NCT02927262
- 5.8 NCT03730012
- 1.7 NCT03730012
- Quizartinib
- 0.0 vs 0.7−0.7 vs placeboNCT02668653
5 other results
- 1.4 vs 0.8 NCT02039726
- 3.2 NCT01565668
- 2.8 NCT01565668
- 2.9 NCT02984995
- 0.0 NCT02984995
Duration of response, median
- Gilteritinib
- 14.8 vs 1.8vs Salvage ChemotherapyNCT02421939
- Quizartinib
- 3.6bNCT00989261
3 other results
- 3.3 NCT00989261
- 5.2 NCT00989261
- 1.9 NCT00989261
- b Single-arm result: the trial had no control arm, so the number has no comparator and does not compare with a randomised result.
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
5 other shared endpoints and safety
Coverage. Gilteritinib: 9 of 9 rows · Quizartinib: 9 of 9 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | Gilteritinib Rows use multiple source trials | Quizartinib Rows use multiple source trials |
|---|---|---|
| Complete Remission responder rate · % of participants No placebo or comparator arm | 33.3% (n=3)120 mg + 420 mga,b,c,d,e NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination show 1 more dose0% (n=8)120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination | 2.6% (n=38) @ 156wk*60 mga,b,c,d,e NCT01565668 · Phase 2 · registry result, not featured evidence · converted to % from 1 Participants as posted show 1 more dose5.3% (n=38) @ 156wk*30 mg NCT01565668 · Phase 2 · registry result, not featured evidence · converted to % from 2 Participants as posted |
| CRc responder rate · % of participants No placebo or comparator arm | 33.3% (n=3)120 mg + 420 mga,b,f,d,e NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination show 1 more dose12.5% (n=8)120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination | 56.5% (n=23)30 mg/daya,b,f,d,e NCT02984995 · Phase 2 · registry result, not featured evidence show 1 more dose33.3% (n=3)20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence |
| Duration of Response time to event · months No placebo or comparator arm | NA months120 mg + 420 mga,b,f,d,e NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination show 1 more doseNA months120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination | 3.62 months*a,b,f,d,e NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 15.7 weeks as posted show 3 more doses5.17 months* NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 22.4 weeks as posted 3.25 months* NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 14.1 weeks as posted 1.87 months* NCT00989261 · Phase 2 · registry result, not featured evidence · converted to months from 8.1 weeks as posted |
| Event Free Survival time to event · months No placebo or comparator arm | 5.75 months*120 mg + 420 mga,b,f,d,e NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 175 days as posted show 1 more dose1.72 months*120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 52.5 days as posted | 2.93 months*30 mg/daya,b,f,d,e NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 12.7 weeks as posted show 1 more dose0.02 months*20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 0.1 weeks as posted |
| Overall Survival time to event · months No placebo or comparator arm | NA months120 mg + 420 mga,b,f,d,e NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination show 1 more dose5.75 months*120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination · converted to months from 175 days as posted | 7.87 months*30 mg/daya,b,f,d,e NCT02984995 · Phase 2 · registry result, not featured evidence · converted to months from 34.1 weeks as posted show 1 more doseNA months20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence |
| Dropout rate | 31.5%g NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results—Randomized Cohort: Gilteritinib NCT02752035 · Phase 3 · monotherapy —Randomized Cohort: Gilteritinib + NCT02752035 · Phase 3 · combination n/a: no completion milestoneSafety Cohort: Gilteritinib + Azac NCT02752035 · Phase 3 · combination 100% NCT02421939 · Phase 3 61.9% NCT02927262 · Phase 2 · registry result, not featured evidence n/a: no completion milestone120 mg + 420 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination n/a: no completion milestone120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 100%200 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 100%120 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 66.7%80 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 100%40 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence n/a: no completion milestone20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence | 79.1%g NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results18.4% NCT02039726 · Phase 3 · registry result, not featured evidence 73.5%30 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence —20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 100%20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence n/a: no completion milestone60 mg NCT01565668 · Phase 2 · registry result, not featured evidence n/a: no completion milestone30 mg NCT01565668 · Phase 2 · registry result, not featured evidence 9.6%Cohort 1; ≥60 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 12.5%Cohort 2; ≥18 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 0%Phase 1 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 2 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 2 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 66.7%40 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence 50%20 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence 100%60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 16.7%60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 0%40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 20%40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 0%25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 1 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —450 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —135 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —90 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —60 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —40 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —27 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —18 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —12 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence |
| Discontinued due to AEs | —g NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results—Randomized Cohort: Gilteritinib NCT02752035 · Phase 3 · monotherapy —Randomized Cohort: Gilteritinib + NCT02752035 · Phase 3 · combination 6.7%Safety Cohort: Gilteritinib + Azac NCT02752035 · Phase 3 · combination 13% NCT02421939 · Phase 3 11.1% NCT02927262 · Phase 2 · registry result, not featured evidence 0%120 mg + 420 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 12.5%120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination —200 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence —450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 17.6%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 25%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 20.6%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 7.2%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 9.5%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 13.3%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 0%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence | 21.6%g NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results— NCT02039726 · Phase 3 · registry result, not featured evidence 2.9%30 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence —20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 0%20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 2.6%60 mg NCT01565668 · Phase 2 · registry result, not featured evidence 15.8%30 mg NCT01565668 · Phase 2 · registry result, not featured evidence —Cohort 1; ≥60 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence —Cohort 2; ≥18 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence —Phase 1 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —Phase 1 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —Phase 2 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination —40 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence —20 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —ALL Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 1 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence —AML Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence —450 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —300 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence —200 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —135 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —90 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —60 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —40 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —27 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —18 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence —12 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence |
| Serious AEs | 51.7%g NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results90.9%Randomized Cohort: Gilteritinib NCT02752035 · Phase 3 · monotherapy 92%Randomized Cohort: Gilteritinib + NCT02752035 · Phase 3 · combination 93.3%Safety Cohort: Gilteritinib + Azac NCT02752035 · Phase 3 · combination 85.8% NCT02421939 · Phase 3 38.7% NCT02927262 · Phase 2 · registry result, not featured evidence 100%120 mg + 420 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 87.5%120 mg + 840 mg NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 0%200 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 66.7%120 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 33.3%80 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 100%40 mg NCT02561455 · Phase 1/2 · registry result, not featured evidence 66.7%450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —450 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 82.4%300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —300 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 92%200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —200 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 33.3%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 78.8%120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —120 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 90.5%80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —80 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 92.3%40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —40 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 40%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence 66.7%20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence —20 mg NCT02014558 · Phase 1/2 · registry result, not featured evidence | 55.1%g NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 37 more results69.7% NCT02039726 · Phase 3 · registry result, not featured evidence 41.2%30 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 100%20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence —20 mg/day NCT02984995 · Phase 2 · registry result, not featured evidence 63.9%60 mg NCT01565668 · Phase 2 · registry result, not featured evidence 65.8%30 mg NCT01565668 · Phase 2 · registry result, not featured evidence 85.4%Cohort 1; ≥60 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 76.7%Cohort 2; ≥18 Years of Age NCT00989261 · Phase 2 · registry result, not featured evidence 20%Phase 1 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 0%Phase 1 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 40%Phase 2 Arm I (Quizartinib, Azacit NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 65.6%Phase 2 Arm II (Quizartinib, Cytar NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 66.7%40 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence 0%20 mg/day NCT02834390 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —60mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —40mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence —25mg/m^2/Day NCT01411267 · Phase 1 · registry result, not featured evidence 50%ALL Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence 0%ALL Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence 66.7%AML Dose Level 1 NCT01411267 · Phase 1 · registry result, not featured evidence 60%AML Dose Level 2 NCT01411267 · Phase 1 · registry result, not featured evidence 40%AML Dose Level 3 NCT01411267 · Phase 1 · registry result, not featured evidence 83.3%450 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 100%300 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence 75%300 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 52.9%200 mg CD NCT00462761 · Phase 1 · registry result, not featured evidence 50%200 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 80%135 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 66.7%90 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 80%60 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 60%40 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 16.7%27 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 50%18 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence 33.3%12 mg ID NCT00462761 · Phase 1 · registry result, not featured evidence |
| Most frequent reported AEs | g chronic graft versus host disease 52.8% (placebo 43.5%) acute graft versus host disease 37.6% (placebo 36.2%) neutrophil count decreased 27.5% (placebo 9.6%) NCT02997202 · Phase 3 · monotherapy · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 24 more resultsanaemia 45.5% alanine aminotransferase increased 40.7% aspartate aminotransferase increased 39.4% NCT02421939 · Phase 3 blood creatine phosphokinase increased 29% (placebo 2.9%) neutrophil count decreased 19.4% (placebo 8.6%) platelet count decreased 19.4% (placebo 11.4%) NCT02927262 · Phase 2 · registry result, not featured evidence 120 mg + 420 mg decreased appetite 100% dizziness 100% dyspnoea 100% NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 120 mg + 840 mg diarrhoea 50% fatigue 50% nausea 50% NCT03730012 · Phase 1/2 · registry result, not featured evidence · combination 200 mg benign breast neoplasm 100% cough 100% covid-19 100% NCT02561455 · Phase 1/2 · registry result, not featured evidence 120 mg cough 66.7% decreased appetite 66.7% diarrhoea 66.7% NCT02561455 · Phase 1/2 · registry result, not featured evidence 80 mg anorectal discomfort 33.3% anxiety 33.3% arthralgia 33.3% NCT02561455 · Phase 1/2 · registry result, not featured evidence 40 mg cough 100% muscle spasms 100% abdominal discomfort 50% NCT02561455 · Phase 1/2 · registry result, not featured evidence 450 mg aspartate aminotransferase increased 66.7% hyperglycaemia 66.7% abdominal pain 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 300 mg pollakiuria 66.7% alanine aminotransferase increased 33.3% anaemia 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 300 mg anaemia 35.3% diarrhoea 29.4% epistaxis 23.5% NCT02014558 · Phase 1/2 · registry result, not featured evidence 200 mg fatigue 100% abdominal pain 33.3% aspartate aminotransferase increased 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 200 mg diarrhoea 45% aspartate aminotransferase increased 35% anaemia 33% NCT02014558 · Phase 1/2 · registry result, not featured evidence 120 mg constipation 66.7% abdominal pain lower 33.3% blood bilirubin increased 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 120 mg anaemia 40.9% diarrhoea 40.9% fatigue 40.9% NCT02014558 · Phase 1/2 · registry result, not featured evidence 80 mg decreased appetite 66.7% nausea 66.7% vomiting 66.7% NCT02014558 · Phase 1/2 · registry result, not featured evidence 80 mg fatigue 38.1% anaemia 33.3% cough 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 40 mg constipation 33.3% dizziness 33.3% dry skin 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence 40 mg dyspnoea 38.5% fatigue 38.5% anaemia 30.8% NCT02014558 · Phase 1/2 · registry result, not featured evidence 20 mg anaemia 40% nausea 40% abdominal pain 20% NCT02014558 · Phase 1/2 · registry result, not featured evidence 20 mg hypokalaemia 41.7% fatigue 33.3% oedema peripheral 33.3% NCT02014558 · Phase 1/2 · registry result, not featured evidence | g pyrexia 42.6% (placebo 39.6%) febrile neutropenia 37% (placebo 36.2%) diarrhoea 36.6% (placebo 35.1%) NCT02668653 · Phase 3 · Acute Myeloid Leukemia, Hematologic Malignancies · phase 3 show 30 more results30 mg/day platelet count decreased 38.2% electrocardiogram qt prolonged 35.3% febrile neutropenia 29.4% NCT02984995 · Phase 2 · registry result, not featured evidence 20 mg/day nausea 66.7% transfusion reaction 66.7% anemia 33.3% NCT02984995 · Phase 2 · registry result, not featured evidence 60 mg nausea 47.2% pyrexia 38.9% diarrhea 36.1% NCT01565668 · Phase 2 · registry result, not featured evidence 30 mg anemia 47.4% fatigue 34.2% febrile neutropenia 31.6% NCT01565668 · Phase 2 · registry result, not featured evidence nausea 54.1% diarrhea 41.4% fatigue 39.5% NCT00989261 · Phase 2 · registry result, not featured evidence nausea 50.6% vomiting 39.8% diarrhea 38.1% NCT00989261 · Phase 2 · registry result, not featured evidence alanine aminotransferase increased 80% blood bilirubin increased 80% hypocalcemia 80% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination alanine aminotransferase increased 100% allergic rhinitis 100% anemia 100% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination hypomagnesemia 65.7% creatinine decreased 62.9% hypokalemia 62.9% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination pain 50% nausea 43.8% diarrhea 40.6% NCT01892371 · Phase 1/2 · registry result, not featured evidence · combination 40 mg/day electrocardiogram qt prolonged 100% febrile neutropenia 100% alopecia 66.7% NCT02834390 · Phase 1 · registry result, not featured evidence 20 mg/day febrile neutropenia 100% abdominal pain upper 75% alopecia 75% NCT02834390 · Phase 1 · registry result, not featured evidence platelet count decreased 100% anemia 50% ara-c skin rash 50% NCT01411267 · Phase 1 · registry result, not featured evidence hypokalemia 100% anemia 50% arthralgia 50% NCT01411267 · Phase 1 · registry result, not featured evidence anemia 100% white blood cell decreased 100% alanine aminotransferase increased 66.7% NCT01411267 · Phase 1 · registry result, not featured evidence white blood cell decreased 100% anemia 80% febrile neutropenia 60% NCT01411267 · Phase 1 · registry result, not featured evidence hypokalemia 90% hypomagnesemia 80% platelet count decreased 70% NCT01411267 · Phase 1 · registry result, not featured evidence 450 mg ID asthenia 66.7% diarrhoea 66.7% disease progression 66.7% NCT00462761 · Phase 1 · registry result, not featured evidence 300 mg CD ecg qt prolonged 50% anaemia 37.5% cough 37.5% NCT00462761 · Phase 1 · registry result, not featured evidence 300 mg ID anaemia 50% dyspnoea 50% fatigue 50% NCT00462761 · Phase 1 · registry result, not featured evidence 200 mg CD pyrexia 41.2% vomiting 41.2% epistaxis 35.3% NCT00462761 · Phase 1 · registry result, not featured evidence 200 mg ID nausea 83.3% chills 50% diarrhoea 50% NCT00462761 · Phase 1 · registry result, not featured evidence 135 mg ID fatigue 60% febrile neutropenia 60% nausea 40% NCT00462761 · Phase 1 · registry result, not featured evidence 90 mg ID febrile neutropenia 100% headache 66.7% nausea 66.7% NCT00462761 · Phase 1 · registry result, not featured evidence 60 mg ID disease progression 80% anaemia 60% nausea 60% NCT00462761 · Phase 1 · registry result, not featured evidence 40 mg ID pyrexia 60% anaemia 40% cough 40% NCT00462761 · Phase 1 · registry result, not featured evidence 27 mg ID nausea 50% anaemia 33.3% fatigue 33.3% NCT00462761 · Phase 1 · registry result, not featured evidence 18 mg ID diarrhoea 37.5% dizziness 37.5% hypokalaemia 37.5% NCT00462761 · Phase 1 · registry result, not featured evidence 12 mg ID abdominal pain 66.7% cough 66.7% asthenia 33.3% NCT00462761 · Phase 1 · registry result, not featured evidence |
Notes
- aThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- bTrial phases differ: Phase 1/2 versus Phase 2.
- cPopulation context differs: registered conditions differ.
- dTreatment context has not been resolved for both arms.
- eThe assessment timepoint is not available for both results.
- fPopulation comparability has not been reviewed for both studies.
- gPopulation comparability has not been reviewed for 37 of these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
Gilteritinib
show 1 more result
show 1 more result
show 1 more result
show 2 more results
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 2 more results
+ 27 further endpoints in the CSV export.
Quizartinib
show 5 more results
show 5 more results
show 3 more results
show 1 more result
show 1 more result
show 1 more result
show 5 more results
show 3 more results
+ 13 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: Gilteritinib's landscape · Quizartinib's landscape